Cagrilintide CAS 1415456-99-3 with COA

20 USD

Research tool for obesity mechanisms and combination therapy development.
Pharmaceutical candidate for metabolic disorders, including type 2 diabetes and obesity-related comorbidities.

Comentarii Facebook

Comentarii

Nu s-a postat inca nici un comentariu

Lasa un comentariu

Nu sunteti autentificat. Pentru a putea posta comentarii trebuie sa fiti autentificat in sistem.